What is HC Wainwright’s Forecast for DBVT FY2028 Earnings?

Posted by George Bondi on Oct 30th, 2026

DBV Technologies S.A. (NASDAQ:DBVT – Free Report) – Research analysts at HC Wainwright upped their FY2028 earnings per share estimates for DBV Technologies in a note issued to investors on Thursday, October 29th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of $1.25 per share for the year, up from their previous estimate of $1.15. The consensus estimate for DBV Technologies’ current full-year earnings is ($2.05) per share.

DBV Technologies (NASDAQ:DBVT – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.44). DBV Technologies had a negative net margin of 5,392.17% and a negative return on equity of 115.81%. The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.56 million.

DBVT has been the subject of a number of other research reports. Citigroup reaffirmed a “market outperform” rating on shares of DBV Technologies in a research note on Thursday. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Citizens Jmp dropped their price objective on DBV Technologies from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DBV Technologies in a research note on Thursday, October 15th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $46.50.

View Our Latest Research Report on DBV Technologies

DBV Technologies Stock Performance

DBV Technologies stock opened at $10.29 on Friday. The firm’s fifty day moving average price is $11.62 and its 200-day moving average price is $16.97. The stock has a market cap of $647.01 million, a P/E ratio of -3.42 and a beta of -1.04. DBV Technologies has a fifty-two week low of $8.63 and a fifty-two week high of $26.18.

Hedge Funds Weigh In On DBV Technologies

A number of institutional investors and hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC bought a new position in DBV Technologies during the 1st quarter valued at approximately $21,159,000. Perceptive Advisors LLC bought a new stake in DBV Technologies in the first quarter worth $20,146,000. Elmind Capital LP bought a new stake in DBV Technologies in the first quarter worth $5,536,000. Vivo Capital LLC boosted its holdings in DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after acquiring an additional 205,943 shares in the last quarter. Finally, Dorsey Wright & Associates purchased a new stake in shares of DBV Technologies in the first quarter worth $2,142,000. Institutional investors own 71.74% of the company’s stock.

Key Stories Impacting DBV Technologies

Here are the key news stories impacting DBV Technologies this week:

Positive Sentiment: DBV submitted its Biologics License Application to the U.S. FDA for the VIASKIN Peanut Patch in children ages 4–7 and requested Priority Review. The company is also accelerating commercial preparations for a potential U.S. launch, which could be a major catalyst if the application is accepted and approved. DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
Positive Sentiment: The company reported $165.7 million in cash and equivalents as of September 30, 2026, which management said provides funding into the third quarter of 2027. This reduces near-term financing pressure while the regulatory process advances. DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
Positive Sentiment: Citizens JMP maintained a “market outperform” rating, indicating continued confidence in the long-term opportunity despite reducing its price target to $47 from $55. DBV Technologies Price Target Lowered at Citizens
Neutral Sentiment: Third-quarter revenue was $1.60 million, above the $0.58 million analyst estimate, but the result remains small relative to the company’s development and commercialization costs. DBV Technologies Third-Quarter Earnings Results
Negative Sentiment: DBV reported a quarterly loss of $0.70 per share, substantially worse than the $0.29 loss analysts expected. The company continues to report deeply negative margins and return on equity. DBV Technologies Reports Wider Third-Quarter Loss
Negative Sentiment: The price-target reduction reflects concerns about manufacturing risk during the company’s transition toward commercial readiness, making regulatory and production execution key near-term risks. DBV Technologies Third-Quarter 2026 Earnings Call Transcript

About DBV Technologies

(Get Free Report)

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.